Abstract: Disclosed are a crystalline form or an amorphous form of a macrocyclic compound or a salt or solvate thereof, as well as a preparation method therefor and an application thereof. The structure of the macrocyclic compound is represented by formula I.

Abstract: The present invention relates to a pharmaceutical composition containing alkynyl compound, a preparation method thereof and its application. The present invention discloses a pharmaceutical composition comprising an active pharmaceutical ingredient and an available pharmaceutical excipient; The active pharmaceutical ingredient is 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-benzamide, or its pharmaceutical acceptable salt; The available pharmaceutical excipients includes diluents and lubricants. The pharmaceutical composition can effectively improve the bioavailability of the alkynyl compound, has good dissolution and stability, and improve the drug safety.

Abstract: Disclosed herein are a process for preparing alkynyl-containing compound and intermediate thereof.

Abstract: The present invention relates to a pharmaceutical composition containing alkynyl compound, a preparation method thereof and its application. The present invention discloses a pharmaceutical composition comprising an active pharmaceutical ingredient and an available pharmaceutical excipient; The active pharmaceutical ingredient is 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-benzamide, or its pharmaceutical acceptable salt; The available pharmaceutical excipients includes diluents and lubricants. The pharmaceutical composition can effectively improve the bioavailability of the alkynyl compound, has good dissolution and stability, and improve the drug safety.

Abstract: Disclosed in the present application are a concrete protection material, and a preparation method and a construction method therefor. The concrete protection material consists of 50%-90% of a component A and 10%-50% of a component B in percentage by weight, where the component A is prepared from 30%-65% of organic silicon, 2%-5% of nano-silicon dioxide and the balance of an organic solvent in percentage by weight; and the component B is prepared from 20%-50% of an organic base and the balance of water in percentage by weight. The present application not only can form nano-particles having a strengthening effect in capillary channels of a concrete surface layer, but also can achieve a technical effect of superhydrophobicity on the concrete surface layer.

Abstract: The invention provides a modified dolomite powder, a preparation method thereof, and a concrete. The modified dolomite powder is prepared from 98% to 99% of a dolomite powder, 0.2% to 0.5% of a chaotropic agent, 0.6% to 1.0% of a dihydrogen phosphate, and 0.2% to 0.5% of a capillary filler according to the mass percentage. The chaotropic agent is one or more of sodium sulfate, potassium sulfate, and ammonium sulfate. By promoting the dissolution of the surface of the dolomite powder, participating in the hydration reaction, and filling capillary pores, the triple modification solves the problems of bleeding, strength, and durability of the dolomite powder concrete in the related art. The obtained modified dolomite powder has good solubility and high chemical activity, and the prepared concrete has high strength and compactness, low porosity, and good durability.

Abstract: Disclosed is a method for preparing 2-indolinospirone compound and intermediate thereof, specifically disclosed is a method for preparing a compound of formula 5. The method is relatively simple and has high stereoselectivity and yield.

Abstract: Disclosed herein are a crystalline or amorphous form of a Bcl-2/Bcl-xL inhibitor compound or a salt thereof, and a preparation method and application thereof.

Abstract: Crystallines form or amorphous forms of bisdiazabicyclic compounds or salts thereof for the treatment and/or prevention of diseases or disorders related to hepatitis virus, and a preparation method and application thereof are provided. The crystalline forms or amorphous forms involved provide important reference value for the development and utilization of drugs in the future.

Abstract: The present invention provides crystalline forms or amorphous forms of N-(phenylsulfonyl) benzoamide compound or its salts or solvates used as a Bcl-2 inhibitor, and the preparation method and the application thereof.

Abstract: Disclosed is a method for synthesizing N-(phenylsulfonyl)benzamide compound and intermediate thereof. The method comprises a method for synthesizing a compound 1, comprising conducting a Buchwald-Hartwig coupling reaction as shown below with compound A and compound B in a solvent and in the presence of a base and a palladium catalyst to obtain the compound 1; wherein R is C1-C8 alkyl. The present disclosure synthesizes three intermediate compounds required by the target compound and their preparation methods for the first time. Using the method disclosed in the present disclosure to synthesize the target compound 3 has the advantages of high yield, good purity, easy-to-obtain reaction raw materials, suitable for industrial production.

Abstract: This disclosure relates to processing sequential interaction data through machine learning. In one aspect, a method includes obtaining a dynamic interaction graph constructed based on a dynamic interaction sequence. The dynamic interaction sequence includes interaction feature groups corresponding to interaction events. Each interaction feature group includes a first object, a second object, and an interaction time of an interaction event that involved the first object and the second object. The dynamic interaction graph includes multiple nodes including, for each interaction feature group, a first node that represents the first object of the interaction feature group and a second node that represents the second object of the interaction feature group. A current sequence corresponding to a current node to be analyzed is determined. The current sequence is input into a Transformer-based neural network model. The neural network model determines a feature vector corresponding to the current node.

Abstract: The invention discloses the crystal form, preparation method and application of an alkynyl compound, its salt and solvent compound. The invention specifically discloses 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl) benzamide crystal form I and 3-((1H-pyrazolo [3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl) benzamide fumarate crystal form II. The crystal form of the invention has good stability and has important value for drug optimization and development.

Abstract: Amorphous form or crystalline form of a 2-indolinolinololylspironone compound or its salt and solvate used as an MDM2 inhibitor, a preparation method and an application thereof. The amorphous form or crystalline form of the invention has good stability and is of great value for drug development, preparation development and production.

Abstract: The present invention relates to a pharmaceutical composition containing alkynyl compound, a preparation method thereof and its application. The present invention discloses a pharmaceutical composition comprising an active pharmaceutical ingredient and an available pharmaceutical excipient; The active pharmaceutical ingredient is 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-benzamide, or its pharmaceutical acceptable salt; The available pharmaceutical excipients includes diluents and lubricants. The pharmaceutical composition can effectively improve the bioavailability of the alkynyl compound, has good dissolution and stability, and improve the drug safety.

Abstract: The present invention relates to a method for preparing sulfonamides which are inhibitors of Bcl-2/Bcl-xL, comprising the compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)-phenylaminosulfonyl)-2-trifluoro methylsulfonyl-anilino)-4-phenylthio-butyl)-4-hydroxyl-piperidine, and the present invention also relates to intermediates for the preparation of the sulfonamides, a new final product and its therapeutic use, and pharmaceutical use.

Abstract: The present invention relates to a process for preparing a sulfonamide compound which is an inhibitor of Bcl-2/Bcl-xL, including the compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrol-3-yl)-5-fluorophenyl)piperazine-1-yl)-phenylaminosulfonyl)-2-trifluoromethanesulfonyl-anilino)-4-phenylthio-butyl)-piperidine-4-carboxylic acid 3-phosphonopropyl ester. The present invention also relates to an intermediate for preparing the sulfonamide compound and a preparation process thereof.

Abstract: Disclosed herein are a process for preparing alkynyl-containing compound and intermediate thereof.

Abstract: Computer-implemented methods, computer-implemented systems, and non-transitory, computer-readable media for processing interaction sequence data are disclosed. One computer-implemented method includes: obtaining a dynamic interaction graph is obtained, where the dynamic interaction graph is constructed based on a dynamic interaction sequence, including a plurality of interactions arranged in a chronological order, where each interaction includes two objects involved in the interaction and a time of the interaction. In the dynamic interaction graph, a sub-graph corresponding to a target node is determined, where nodes in the sub-graph comprise the target node and connection nodes connected to the target node through a predetermined amount of edges originating from the target node. A feature vector corresponding to the target node is determined based on a node feature of each of the nodes of the sub-graph and directions of edges of the sub-graph.